Trends in the antihypertensive drugs consumption in the population of several regions of the Russian Federation
- Authors: Blinkova P.R.1, Petrukhina I.K.1, Lebedev P.A.1, Ryazanova T.K.1, Gladunova E.P.1
-
Affiliations:
- Samara State Medical University
- Issue: Vol 24, No 1 (2024)
- Pages: 43-51
- Section: ORGANIZATION OF THE PHARMACEUTICAL BUSINESS
- URL: https://journals.rcsi.science/2410-3764/article/view/263402
- DOI: https://doi.org/10.35693/AVP613201
- ID: 263402
Cite item
Full Text
Abstract
Aim – to study the consumption patterns for antihypertensives in the population of individual regions of the Russian Federation (using the example of Moscow and St. Petersburg).
Material and methods. The raw data was collected using the following methods: content analysis, structural, comparative, logical, systemic, predictive, retrospective, graphic and marketing analysis. The results were normalized and processed using methods of mathematical statistics. The research focused on statistics for the range of antihypertensive drugs sold in the retail sector of the pharmaceutical market in Moscow and St. Petersburg.
Results. Moscow and St. Petersburg presented a wide range of drugs sold for treatment of arterial hypertension. Single active ingredient drugs predominated in the sales structure of both regions (Moscow – 90.08%; St. Petersburg – 85.64%). The consumption leaders among single active ingredient drugs were: ACE inhibitors (26.62%) in Moscow, and β-blockers (25.67%) in St. Petersburg. Among the fixed-dose combination drugs, the ACE inhibitors in combination with diuretics were leading in both regions, accounting for 3.54% and 5.15% in the structure of sales in Moscow and St. Petersburg, respectively. The most popular single active ingredient drugs and fixed-dose combination drugs for treating hypertension were rated. Several correlations were identified using mathematical and statistical analysis.
Conclusion. We have identified the most consumed classes of antihypertensives and INNs. We have described the relationship between the sales volumes of drugs prescribed for arterial hypertension (packages), the population size and the incidence of CSD in the studied regions.
Full Text
##article.viewOnOriginalSite##About the authors
Polina R. Blinkova
Samara State Medical University
Author for correspondence.
Email: p.r.blinkova@samsmu.ru
ORCID iD: 0000-0002-8604-0729
assistant of the Department of Management and Economics of Pharmacy
Russian Federation, SamaraIrina K. Petrukhina
Samara State Medical University
Email: i.k.petrukhina@samsmu.ru
ORCID iD: 0000-0001-6207-5575
PhD, Associate professor, Deputy Director of the Institute of Pharmacy, Head of the Department of Management and Economics of Pharmacy
Russian Federation, SamaraPetr A. Lebedev
Samara State Medical University
Email: p.a.lebedev@samsmu.ru
ORCID iD: 0000-0003-3501-2354
PhD, Professor, Head of the Department of Therapy
Russian Federation, SamaraTatyana K. Ryazanova
Samara State Medical University
Email: t.k.ryazanova@samsmu.ru
ORCID iD: 0000-0002-4581-8610
PhD, Associate professor, Department of Management and Economics of Pharmacy, Director of the REC "Pharmacy"
Russian Federation, SamaraElena P. Gladunova
Samara State Medical University
Email: e.p.gladunova@samsmu.ru
ORCID iD: 0000-0001-5198-0393
PhD, Professor, Department of Management and Economics of Pharmacy
Russian Federation, SamaraReferences
- Arterial hypertension in adults. Clinical guidelines 2020. Russian Journal of Cardiology. 2020;25(3):3786. (In Russ.). [Артериальная гипертензия у взрослых. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;25(3):3786]. https://doi.org/10.15829/1560-4071-2020-3-3786
- Kobalava ZhD, Konradi AO, Nedogoda SV. Russian Society of Cardiology position paper on 2018 Guidelines of the European Society of Cardiology/European Society of Arterial Hypertension for the management of arterial hypertension. Russian Journal of Cardiology. 2018;23(12):131-142. (In Russ.). [Кобалава Ж.Д., Конради А.О., Недогода С.В. Меморандум экспертов Российского кардиологического общества по рекомендациям Европейского общества кардиологов / Европейского общества по артериальной гипертензии по лечению артериальной гипертензии 2018 г. Российский кардиологический журнал. 2018;23(12):131-142]. https://doi.org/10.15829/1560-4071-2018-12-131-142
- Chazova IE, Zhernakova YuV. On behalf of the experts. Clinical guidelines. Diagnosis and treatment of arterial hypertension. Systemic Hypertension. 2019;16(1):6-31. (In Russ.). [Чазова И.Е., Жернакова Ю.В. От имени экспертов. Клинические рекомендации. Диагностика и лечение артериальной гипертонии. Системные гипертензии. 2019;16(1):6-31]. https://doi.org/10.26442/2075082X.2019.1.190179
- ESC Guidelines on cardiovascular disease prevention in clinical practice. European Heart Journal. 2021;42:3227-3337. https://doi.org/10.1093/eurheartj/ehab484
- More than 700 million people with untreated hypertension. Number of people living with hypertension has doubled to 1.28 billion since 1990. World Health Organization. 2021. https://www.who.int/news/item/25-08-2021-more-than-700-million-people-with-untreated-hypertension
- Mortality by major causes of death. Russian Statistical Yearbook, 2021. [Смертность по основным классам причин смерти. Российский статистический ежегодник. 2021. https://rosstat.gov.ru/storage/mediabank/Ejegodnik_2021.pdf
- The top 10 causes of death. World Health Organization. 2022. https://www.who.int/ru/news-room/fact-sheets/detail/the-top-10-causes-of-death
- Petrukhina IK, Yagudina RI, Egorova GA, et al. Analysis of main indicators for implementing the essential drugs program for the population of the Samara Region. Pharmacy. 2019;68:33-41. (In Russ.). [Петрухина И.К., Ягудина Р.И., Егорова Г.А., и др. Анализ основных индикативных показателей реализации программы обеспечения необходимыми лекарственными препаратами населения Самарской области. Фармация. 2019;68(1):33-41]. https://doi.org/10.29296/25419218-2019-01-05
- Belousov DYu, Cheberda AE. Pharmacoepidemiological studies: methodology and regulation. Kachestvennaya klinicheskaya praktika. 2017;(1):34-41. (In Russ.). [Белоусов Д.Ю., Чеберда А.Е. Фармакоэпидемиологические исследования: методология и регулирование. Качественная клиническая практика. 2017;(1):34-41].
- Rachina SA, Kozlov RS, Belkova YuA. Pharmacoepidemiology: from theory to practice. Farmakoekonomika. Modern Pharmacoeconomics and Pharmacoepidemiology. 2014;7(1):33-39. (In Russ.). [Рачина С.А., Козлов Р.С., Белькова Ю.А. Фармакоэпидемиология: от теоретических основ к практическому применению. Фармакоэкономика. Современная фармакоэкономика и фармакоэпидемиология. 2014;7(1):33-39].
- Mubarakshina OA, Somova MN, Batishcheva GA. Modern combination antihypertensive pharmacotherapy. Systemic Hypertension. 2018;15(4):30-33. (In Russ.). [Мубаракшина О.А., Сомова М.Н., Батищева Г.А. Современная комбинированная фармакотерапия артериальной гипертензии. Системные гипертензии. 2018;15(4):30-33]. https://doi.org/10.26442/2075082X.2018.4.180149
- Morozova TE. Combined antihypertensive therapy in the light of modern recommendations: strategy of one tablet. Systemic Hypertension. 2018;15(4):92-96. (In Russ.). [Морозова Т.Е. Комбинированная антигипертензивная терапия в свете современных рекомендаций: стратегия одной таблетки. Системные гипертензии. 2018;15(4):92-96]. https://doi.org/10.26442/2075082X.2018.4.180110
- Chazova IE, Aksenova AV, Zhernakova YuV. "Polypill" conception in modern cardiology. Systemic Hypertension. 2018;15 (4):6-7. (In Russ.). [Чазова И.Е., Аксенова А.В., Жернакова Ю.В. Концепция «полипилл» в современной кардиологии. Системные гипертензии. 2018;15(4):6-7]. https://doi.org/10.26442/2075082X.2018.4.180116
Supplementary files
